BCMA / GLuc - CHO Recombinant Cell Line

Catalog #

79830

$7,150 *

Size: 2 vials

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Recombinant CHO-K1 cells constitutively expressing both the human BCMA protein (B-Cell Maturation Antigen or CD269, GenBank accession #NM_001192) and the Gaussia Luciferase (Δ Signal peptide). Surface expression of BCMA was confirmed by flow cytometry.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

●

Synonyms

CHO-K1 cell lne, CD269 cell line

●

Product Data Gallery

FACS analysis of cell surface expression of BCMA in BCMA / GLuc CHO recombinant cells

Luciferase activity of BCMA / GLuc CHO recombinant cells

Product Info

Storage and Usage

Citations

Host Cell Line

CHO-K1

Supplied As

Each vial contains 2 x 10⁶ cells in 1 ml of FBS with 10% DMSO.

Materials Required But Not Supplied

• Thaw Medium 3 (BPS Bioscience, #60186)
• Growth Medium 3F (BPS Bioscience, #79829)
• 96-well tissue culture-treated white clear-bottom assay plate
• Cell lysis buffer
• Coelenterazine (NanoLight, #303)
• Luminometer

UniProt #

Q02223

Mycoplasma Testing

This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.

Background

B-Cell Maturation Antigen (BCMA), also known as CD269, is a cell surface receptor of the TNF receptor superfamily that recognizes B-Cell Activating Factor (BAFF). BCMA is preferentially expressed on mature B-lymphocytes and Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy, not only because of its restricted expression in non-malignant tissue, but also due to its almost universal expression on MM cells. Pre-clinical studies using CAR (Chimeric Antigen Receptor) T-cells targeting BCMA have demonstrated anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy the breakthrough designation for treating Multiple Myeloma.

Storage/Stability

Store in liquid nitrogen immediately upon receipt.

Culture Conditions

For best results, it is highly recommended to use these validated and optimized media from BPS Bioscience. Other preparations or formulations of media may result in suboptimal performance.

Thaw Medium 3 (BPS Bioscience #60186): F-12K Medium supplemented with 10% FBS, 1% Penicillin/Streptomycin.

Growth Medium 3F (BPS Bioscience #79829): F-12K Medium supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 400 μg/ml of Geneticin and 100 μg/ml of Hygromycin B to ensure recombinant expression.

Cells should be grown at 37˚C with 5% CO2 using Growth Medium 3F. BCMA / GLuc cells should exhibit a typical cell division time 14 hours.

Instructions for Use

See assay protocol for detailed instructions.

Shipping Temperature

-80°C

Notes

License Disclosure
Visit bpsbioscience.com/license for the label license and other key information about this product.

Troubleshooting Guide
Visit bpsbioscience.com/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email [email protected].

Warnings

Avoid freeze/thaw cycles.

Scientific Category

CAR-T

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

BCMA / GLuc - CHO Recombinant Cell Line

PRODUCTS

SERVICES

RESOURCES

COMPANY